High dose melphalan in children with advanced malignant disease
A pharmacokinetic study
Original Articles Melphalan, Children, Pharmacokinetics
Received:
Accepted:
- 26 Downloads
- 9 Citations
Summary
Nine children with poor-prognosis malignancies — seven with advanced neuroblastoma and two with metastatic Ewing's sarcoma — were give high doses of melphalan (HDM), 150 mg/m2 (3 patients) and 180 mg/m2 (6 patients), as a ‘late intensification’ agent combined with noncryopreserved autologous bone marrow transplants. Melphalan levels in the plasma decreased biphasically, with mean half-lives of 6.6 min and 3.0 h. At the time of marrow reinfusion (12–21 h after HDM) the melphalan plasma level was generally below 0.1 μg/ml. The renal contribution to melphalan clearance was low, a mean of 5.8% of the injected dose being found in patients' urine over the 12 h following HDM administration. No significant difference was seen in pharmacokinetic parameters between patients undergoing and not undergoing forced diuresis.
Keywords
Sarcoma Melphalan Neuroblastoma Pharmacokinetic Parameter Bone Marrow Transplant
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Preview
Unable to display preview. Download preview PDF.
References
- 1.Baurain R, Deprez-de Campeneere D, Zenebergh A, Trouet A (1982) Plasma levels of doxorubicin after IV bolus injection and infusion of the doxorubicin-DNA complex in rabbits and man. Cancer Chemother Pharmacol 9: 93–96Google Scholar
- 2.Begleiter A, Lam H-Y P, Grover J, Froese E, Goldenberg GJ (1979) Evidence for active transport of melphalan by two amino acid carriers in L5178 Y lymphoblasts in vitro. Cancer Res 39: 353–359Google Scholar
- 3.Bosanquet AG, Gilby ED (1984) Comparison of the fed and fasting states on the absorption of melphalan in mutliple myeloma. Cancer Chemother Pharmacol 12: 183–186Google Scholar
- 4.Champlin RE, Gale RP (1984) Role of bone-marrow transplantation in the treatment of hematologic malignancies and solid tumors: critical review of syngeneic, autologous, and allogeneic transplants. Cancer Treat Rep 68: 145–161Google Scholar
- 5.Chang Y, Alberts DS, Melnick LR, Walson D, Salmon SE (1978) High-pressure liquid chromatographic analysis of melphalan in plasma. J Pharm Sci 67: 679–682Google Scholar
- 6.Cornbleet MA, Corringham RET, Prentice HG, Boesen EM, Mc Elwain TJ (1981) Treatment of Ewing's sarcoma with high-dose melphalan. Cancer Treat Rep 65: 241–244Google Scholar
- 7.Ekert H, Ellis WM, Waters KD, Tauro GP (1982) Autologous bone-marrow rescue in the treatment of advanced tumors of chilhood. Cancer 49: 603–609Google Scholar
- 8.Evans AE, D'Angio GJ, Randolph J (1971) A proposed staging for children with neuroblastoma. Cancer 27: 374–378Google Scholar
- 9.Finklestein JZ, Klemperer MR, Evans AE, Berstein I, Leikin S, Mc Creadie S, Grosfeld J, Hittle R, Weiner J, Sather H, Hammond D (1979) Multiagent chemotherapy for children with metastatic neuroblastoma: a report from the Children's Cancer Study Group. Med Pediatr Oncol 6: 179–188Google Scholar
- 10.Glaubiger D, Makuch R, Schwarz J, Levine AS, Johnson RE (1980) Determination of prognostic factors and their influence on therapeutic results in patients with Ewing's sarcoma. Cancer 45: 2213–2219Google Scholar
- 11.Hoel PG (1947) Introduction to mathematical statistics. John Wiley and Sons, New York, p 88Google Scholar
- 12.Ninane J, Pritchard J, Malpas JS (1981) Treatment of advanced neuroblastoma: does adriamycin contribute? Arch Dis Child 56: 544–548Google Scholar
- 13.Ninane J, Latour MJ, Cornu G, Symann M (1982) Haemopoietic stem cells in noncryopreserved autologous bone-marrow transplant. XIVth Meeting of the International Society of Pediatric Oncology. Bern, Switzerland, Sept. 21–25, 1982Google Scholar
- 14.Pritchard J, Mc Elwain TJ, Graham-Pole J (1982) High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma. Br J Cancer 45: 86–94Google Scholar
- 15.Rosen G, Caparros B, Mosende C, Mc Cormick G, Huvos AG, Marcove RC (1978) Curability of Ewing's sarcoma and consideration for future therapeutic trials. Cancer 41: 888–889Google Scholar
- 16.Shafford EA, Rogers DW, Pritchard J (1984) Advanced neuroblastoma. Improved response rate using a multi-agent regimen (OPEC) including sequential cis-Platinum and VM-26. J Clin Oncol 2: 742–747Google Scholar
- 17.Taha IAK, Ahmad RA, Rogers DW, Pritchard J, Rogers HJ (1983) Pharmacokinetics of melphalan in children following high-dose intravenous injection. Cancer Chemother Pharmacol 10: 212–216Google Scholar
- 18.Vistica DT, Rabon A, Rabinovitz M (1979) Amino acid-conferred protection against melphalan: interference with melphalan therapy by L-leucine, a competitive substrate for transport. Cancer Lett 6: 7–12Google Scholar
Copyright information
© Springer-Verlag 1985